A growing body of evidence is reshaping how cancer is understood, placing the spotlight on intra-tumoral microbiota as powerful yet previously overlooked players within the tumor microenvironment. Far from being sterile, tumors host complex communities of bacteria, fungi, and viruses that actively influence disease progression, immune responses, and treatment outcomes.

A comprehensive new review highlights the growing importance of FOXK2, a versatile transcription factor, in shaping cancer behavior and influencing clinical outcomes across a wide range of tumor types. The article brings together emerging knowledge to clarify how this gene functions in cancer and why it is attracting increasing attention as a potential diagnostic and prognostic marker.

A newly published review highlights the pivotal role of FOXA2, a key transcription factor, in coordinating pancreatic development, maintaining islet cell identity, and regulating glucose homeostasis. The article presents a comprehensive synthesis of current knowledge, positioning FOXA2 as a central regulator that links early organ formation with lifelong metabolic control.

ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at Harvard University's David Rubenstein Treehouse in Boston. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.